Tobacco-Specific Nitrosamines (NNAL, NNN, NAT, and NAB) Exposures in the US Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014)

Baoyun Xia, Benjamin C. Blount, Tonya Guillot, Christina Brosius, Yao Li, Dana M. Van Bemmel, Heather L. Kimmel, Cindy M. Chang, Nicolette Borek, Kathryn C. Edwards, Charlie Lawrence, Andrew Hyland, MacIej L. Goniewicz, Brittany N. Pine, Yang Xia, John T. Bernert, B. Rey De Castro, John Lee, Justin L. Brown, Stephen ArnsteinDiane Choi, Erin L. Wade, Dorothy Hatsukami, Gladys Ervies, Angel Cobos, Keegan Nicodemus, Dana Freeman, Stephen S. Hecht, Kevin Conway, Lanqing Wang

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Introduction: The tobacco-specific nitrosamines (TSNAs) are an important group of carcinogens found in tobacco and tobacco smoke. To describe and characterize the levels of TSNAs in the Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014), we present four biomarkers of TSNA exposure: N′-nitrosonornicotine, N′-nitrosoanabasine, N′-nitrosoanatabine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) which is the primary urinary metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Methods: We measured total TSNAs in 11 522 adults who provided urine using automated solid-phase extraction coupled to isotope dilution liquid chromatography-tandem mass spectrometry. After exclusions in this current analysis, we selected 11 004 NNAL results, 10 753 N′-nitrosonornicotine results, 10 919 N′-nitrosoanatabine results, and 10 996 N′-nitrosoanabasine results for data analysis. Geometric means and correlations were calculated using SAS and SUDAAN. Results: TSNA concentrations were associated with choice of tobacco product and frequency of use. Among established, every day, exclusive tobacco product users, the geometric mean urinary NNAL concentration was highest for smokeless tobacco users (993.3; 95% confidence interval [CI: 839.2, 1147.3] ng/g creatinine), followed by all types of combustible tobacco product users (285.4; 95% CI: [267.9, 303.0] ng/g creatinine), poly tobacco users (278.6; 95% CI: [254.9, 302.2] ng/g creatinine), and e-cigarette product users (6.3; 95% CI: [4.7, 7.9] ng/g creatinine). TSNA concentrations were higher in every day users than in intermittent users for all the tobacco product groups. Among single product users, exposure to TSNAs differed by sex, age, race/ethnicity, and education. Urinary TSNAs and nicotine metabolite biomarkers were also highly correlated. Conclusions: We have provided PATH Study estimates of TSNA exposure among US adult users of a variety of tobacco products. These data can inform future tobacco product and human exposure evaluations and related regulatory activities.

Original languageEnglish (US)
Pages (from-to)573-583
Number of pages11
JournalNicotine and Tobacco Research
Issue number3
StatePublished - Jul 27 2020

Bibliographical note

Publisher Copyright:
© 2020 Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco 2020.


Dive into the research topics of 'Tobacco-Specific Nitrosamines (NNAL, NNN, NAT, and NAB) Exposures in the US Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014)'. Together they form a unique fingerprint.

Cite this